Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 3;1(5):379-385.
doi: 10.21873/cdp.10050. eCollection 2021 Nov-Dec.

Diarrhea in Placebo Arms of Cancer Studies

Birte J Wolff  1 , Johannes E Wolff  2
Affiliations
Review

Diarrhea in Placebo Arms of Cancer Studies

Birte J Wolff et al. Cancer Diagn Progn. .

Abstract

Background/aim: Diarrhea is among the most common adverse events in early oncology clinical trials, and drug causality may be difficult to determine.

Materials and methods: This is a systematic literature review of placebo arms of randomized cancer trials.

Results: Anemia was reported in 95 of 127 placebo monotherapy cohorts. Publications involving healthy volunteers and cancer prevention studies reported lower frequencies than those with cancer patients. The average reported frequency of diarrhea grade 1 or higher among studies in cancer patients was 15%. The maximal reported frequencies for grades 1, 2, 3, 4, 5 were 56, 24, 6, 2, and 0%, respectively.

Conclusion: When higher diarrhea frequencies than those are observed in treatment arms of clinical trials, then drug causality is likely.

Keywords: Meta-analysis; adverse events; cancer; oncology; placebo; randomized; review; systematic review.

PubMed Disclaimer

Conflict of interest statement

BW is attending at Swedish Covenant hospital, and has no conflict of interest. JW is an employee of AbbVie pharmaceuticals Inc., and owns stocks. However, this project was not part of the employment, and the data interpretation reflect the authors personal opinion, not the company.

Figures

Figure 1
Figure 1. Frequency of diarrhea reporting in published randomized clinical cancer trials by grade. Open circles: treatment arms, filled circles: placebo arms. The reported frequency of diarrhea grades 1 and 2 correlated closely with the frequency of grade 0. Those were excluded from the regression-based model used for imputation.
Figure 2
Figure 2. Frequency of diarrhea randomized clinical trials. Open circles: treatment arms, filled circles: placebo arms. Although the correlation between grade 1 and 2 versus grade 3 and 4 was mathematically detectable (R=0.51), it was not close enough to be used for imputation of missing variables.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abraham B, Sellin JH. Drug-induced diarrhea. Curr Gastroenterol Rep. 2007;9(5):365–372. doi: 10.1007/s11894-007-0044-x. - DOI - PubMed
    1. Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019;175(1):5–15. doi: 10.1007/s10549-018-05102-x. - DOI - PMC - PubMed
    1. Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398. doi: 10.1016/j.phrs.2019.104398. - DOI - PubMed
    1. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi: 10.1016/j.ctrv.2016.02.001. - DOI - PubMed
    1. Hill AB. The environment and disease: Association or causation. Proc R Soc Med. 1965;58:295–300. - PMC - PubMed

LinkOut - more resources